BriaCell Therapeutics Corp 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-40101 BRIACELL THERAPEUTICS CORP.(Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act. ☐Accelerated filer☒Smaller reporting company☒Emerging growth company ☐Large accelerated filer☒Non-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes☒No☐ As of March 10, 2026, 7,250,487 common shares, no par value per share, of the Company were issued and outstanding. BRIACELL THERAPEUTICS CORP.Form 10-QTable of Contents PagePart I. Financial Information3 Item 1.Financial Statements3Condensed Consolidated Balance Sheets as of January 31, 2026 (unaudited) and July 31, 2025 (audited)3Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Monthsended January 31, 2026 and 20254Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the Three and Six Monthsended January 31, 2026 and 20255Unaudited Condensed Consolidated Statement of Cash Flows for the Three and Six Months ended January 31, 2026 and20257Notes to Unaudited Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures Regarding Market Risk28Item 4.Controls and Procedures29 Item 1.Legal Proceedings30Item 1A.Risk Factors30Item 2.Unregistered Sales of Equity Securities and Use of Proceeds30Item 3.Defaults Upon Senior Securities30Item 4.Mine Safety Disclosures30Item 5.Other Information30Item 6.Exhibits30 BRIACELL THERAPEUTICS CORP.CONDENSED CONSOLIDATED BALANCE SHEETS BRIACELL THERAPEUTICS CORP.CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS(Unaudited) BriaCell Therapeutics CorpNotes to the Condensed Consolidated Financial Statements(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 1: GENERAL AND GOING CONCERN a.BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) was incorporated under the Business Corporations Act (British Columbia)on July 26, 2006 and is listed on the Toronto Stock Exchange (“TSX”) under the symbol “BCT”. The Company also trades on theNasdaq Capital Market (“NASDAQ”) under the symbols “BCTX”, “BCTXW” “BCTXZ”, and “BCTXL”. b.BriaCell is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. The Companyis currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) ina pivotal1Phase 3 study in metastatic breast cancer. Bria-IMT™ is currently under Fast Track Designation by the U.S. Food and DrugAdministration (the “FDA”) intended to accelerate the review process of novel treatments that address unmet medical needs. Positivecompletion of the pivotal study, following review by FDA, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitorcombinationin metastatic breast cancer.BriaCell Phase 1/2 Study of Bria-OTS™,BriaCell’s personalized off-the-shelfimmunotherapy, also known as Bria-BRES™, in metastatic breast cancer is ongoing BriaCell is currently developing Bria-OTS™ andits advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for numerous types ofcancer. The Company announced BriaCell had received positive feed